The effect of dose on safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination. A phase 2, randomized, double-blind, dose-response study.
Latest Information Update: 20 Feb 2014
At a glance
- Drugs ACAM 2000 (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 14 Jan 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 14 Jan 2009.
- 30 Sep 2008 Actual patients number added 274 as reported by ClinicalTrials.gov.
- 30 Sep 2008 Planned end date (1 Sep 2003) added as reported by ClinicalTrials.gov.